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Abstract
An important role in atherogenesis is played by oxidative stress, which may be induced by common
risk factors. Mitochondria are both sources and targets of reactive oxygen species, and there is
growing evidence that mitochondrial dysfunction may be a relevant intermediate mechanism by
which cardiovascular risk factors lead to the formation of vascular lesions. Mitochondrial DNA is
probably the most sensitive cellular target of reactive oxygen species. Damage to mitochondrial
DNA correlates with the extent of atherosclerosis. Several cardiovascular risk factors are
demonstrated causes of mitochondrial damage. Oxidized low density lipoprotein and
hyperglycemia may induce the production of reactive oxygen species in mitochondria of
macrophages and endothelial cells. Conversely, reactive oxygen species may favor the development
of type 2 diabetes mellitus, mainly through the induction of insulin resistance. Similarly - in addition
to being a cause of endothelial dysfunction, reactive oxygen species and subsequent mitochondrial
dysfunction - hypertension may develop in the presence of mitochondrial DNA mutations. Finally,
other risk factors, such as aging, hyperhomocysteinemia and cigarette smoking, are also associated
with mitochondrial damage and an increased production of free radicals. So far clinical studies have
been unable to demonstrate that antioxidants have any effect on human atherogenesis.
Mitochondrial targeted antioxidants might provide more significant results.
Introduction
There is a wide consensus that atherosclerosis (ATS) is an
inflammatory disease associated with lipid and protein
oxidation in the vascular wall [1-5]. At sites of inflamma-
tion, the local cellular environment is enriched with
cytokines, chemoactractant chemokines and reactive oxy-
gen species (ROS), such as superoxide anion, mainly pro-
duced by the activated leukocytes adhering to the
endothelium. Excess ROS and reactive nitrogen species
(RNS) generation has been associated with vascular lesion
formation and functional defects [6-8]. ROS and RNS free
radicals are molecules or molecular fragments containing
one or more unpaired electrons in atomic or molecular
orbitals. The unpaired electrons give the radicals a high
degree of reactivity.
ROS, as well as RNS, are products of normal cellular
metabolism. When there is an overproduction of ROS/
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RNS or a deficiency of enzymatic or non-enzymatic anti-
oxidants, a biological damage to cellular lipids (lipoper-
oxidation), proteins, glucides and DNA may occur.
Moreover, nitric oxide (NO) levels are reduced, due to
both decreased production and increased consumption,
with possible endothelial dysfunction and vascular
impairment [9]. These harmful effects are termed oxida-
tive and nitrosative stress [10].
The toxic effects of free radicals on biomolecules lead to
the accumulation of damage in various cellular locations
and to the deregulation of redox-sensitive metabolic and
signaling pathways, and are also believed to be involved
in pathological conditions such as ATS, hypertension,
inflammation, diabetes, cancer and other human pathol-
ogies. There is evidence that common risk factors for cor-
onary artery disease are associated with increased levels of
ROS [11-16].
Recent studies have focused on the role that mitochondria
could play in atherogenesis. In fact, mitochondria are
both important sources and targets of ROS [14,15]. The
mitochondrial dysfunction theory postulates that excess
release of ROS and RNS from mitochondria can contrib-
ute to the inflammatory vascular reaction leading to the
development of atherosclerotic lesions [17,18]. In fact,
increased mitochondrial ROS production causes endothe-
lial dysfunction, vascular smooth muscle cell (VSMC)
proliferation and apoptosis of VSMCs and macrophages,
with ensuing ATS lesion progression and possible plaque
rupture [18].
Common cardiovascular risk factors could be involved in
this process by adversely affecting the function of
endothelial mitochondria, and growing evidence sup-
ports the hypothesis that mitochondrial dysfunction may
be the most important unifying mechanism explaining
the atherogenic action of major cardiovascular risk factors
[17-19]. This review will discuss the molecular mecha-
nisms by which atherosclerotic risk factors could lead to
mitochondrial dysfunction and subsequent vascular
impairment.
ROS and RNS production in mitochondria
ROS include free radicals (mainly superoxide anion and
hydroxyl) and normal molecules (such as hydrogen per-
oxide [H2O2] and ozone), some of which can be intercon-
verted enzymatically [20]. For example, superoxide is
converted to H2O2 by a family of metallo enzymes such as
manganese superoxide dismutase (Mn SOD) or copper/
zinc superoxide dismutase (Cu/Zn SOD) [21,22]. In turn,
in the presence of reduced transition metals, H2O2 is
mostly transformed in water by glutathione peroxidase or
peroxidredoxin III (PRX III) [23].
Superoxide anion is considered the 'primary' ROS. It may
be formed in the cytosol by reduction of molecular oxy-
gen by the NADPH oxidase and xanthine oxidase. Other
cytosolic or membrane-bound sources of ROS are the
uncoupled endothelial nitric oxide (NO) synthase
(eNOS) and the arachidonate metabolizing enzymes
lipoxygenases and cycloxygenases. However, the mito-
chondrial respiratory chain is the major source of ROS in
most mammalian cells [24-26].
Superoxide anion production can occur at complex I and
III in mitochondria [27,28]. Several factors can regulate
mitochondrial ROS generation. Zhang and Gutterman
[24] have recently reviewed the main molecular pathways
of ROS production, focusing on the effects of mitochon-
drial membrane potential, intracellular Ca2+, elec-
trophilic lipids, and NO.
Nitrosative stress occurs when the generation of RNS in a
biological system exceeds its ability to neutralize them
[29,30]. Nitric oxide (NO) is a reactive radical acting as an
important signaling molecule in several physiological
processes. NO and superoxide can react together to pro-
duce peroxynitrite anion, which is a potent oxidizing
agent capable of causing oxidative damage to biomole-
cules with subsequent inhibition of their biological func-
tion [10].
Mitochondrial ROS and RNS, as well as their metabolic
products such as oxidized lipids, can also play a role in
signal transduction through specific modifications of cell
signaling proteins [31-33]. ROS generation in mitochon-
dria is influenced by multiple factors, including the effi-
ciency of the electron transport chain, oxygen
concentration, the availability of electron donors such as
NADH and FADH2, the activity of UCPs and cytokines,
the activity of antioxidant defenses and the modulation of
nuclear factors [17,34,35]. In this respect, a novel area of
medical research is now developing.
The role of uncoupling proteins (UCPs) in regulating ROS 
production
The mitochondrial respiratory chain requires the expres-
sion of gene products encoded by both the nuclear and
mitochondrial genome [36]. Human mitochondrial
genome consists of 37 genes coding for 13 proteins that
function as subunits for the respiratory complexes I, III,
IV, and V, whereas the genes coding for complex II are
entirely nuclear. Nuclear genes play a major role in the
biosynthesis of the respiratory chain and the expression of
mitochondrial DNA, and all regulatory factors directing
the expression of both nuclear and mitochondrial respira-
tory genes are of nuclear origin [36].Journal of Biomedical Science 2009, 16:112 http://www.jbiomedsci.com/content/16/1/112
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UCPs are mitochondrial anion transporters present in the
inner mitochondrial membrane, and their role in the con-
trol of energy conversion in mitochondria has recently
been demonstrated. The activation of these anion trans-
porters allows protons to leak back into the mitochon-
drial matrix, thus decreasing mitochondrial membrane
potential and ROS generation [37,38]. UCP2 overexpres-
sion inhibits ROS production and apoptosis induced by
linoleic acid and lysophosphatidylcholine [39]. Superox-
ide activates UCPs, with subsequent down-regulation of
its own production [40,41].
The transcriptional regulation of UCP genes, particularly
UCP3 genes, is mediated to a large extent by peroxisome
proliferator activated receptors (PPARs) both in normal
conditions and in metabolic diseases such as diabetes or
obesity [42]. PPARs, as well as liver × receptors, are
nuclear receptors significantly involved in the control of
lipid metabolism, inflammation, insulin sensitivity and,
probably, ATS progression [1,43]. Moreover, PPARs regu-
late the transcription of mitochondrial and microsomal
enzymes [44]. Nunn et al [45] have recently reviewed the
involvement of PPARs in modulating mitochondrial pro-
ton uncoupling and ROS production.
Mitochondrial oxidative dysfunction
Damage to mitochondria is caused primarily by the ROS
generated by mitochondria themselves [34,46], mainly
due to the release of electrons by the coenzymes NADH
and FADH into the electron transport chain. In addition,
a significant amount of ROS can be produced by the
enzymes alpha-ketoglutarate dehydrogenase and
monoamine oxidase located in the outer membrane of
mitochondria [47,48].
The deleterious effects resulting from the formation of
ROS in mitochondria are prevented to a large extent by
various antioxidant systems. Under normal conditions
there is a balance between ROS formation and antioxi-
dants. However, when the antioxidant defenses become
insufficient and cannot convert ROS to H2O2 fast enough,
oxidative damage occurs and accumulates in the mito-
chondria [49]. Interestingly, free fatty acids (FFA) can
decrease the mitochondrial generation of ROS under con-
ditions of reverse electron transport, due to their uncou-
pling action. However, under conditions of forward
electron transport, FFA increase ROS production [50].
Although somewhat controversial [51], an NO produc-
tion does seem to occur in mitochondria through differ-
ent pathways [52-55]. The NO produced in mitochondria
[52,53] counteracts superoxide at multiple levels. It can
rapidly scavenge superoxide via direct radical-radical reac-
tion to form peroxynitrite, a potent oxidant [56-60] capa-
ble of decreasing the activity of complex I by forming S-
nitrosothiols [61]. This in turn reduces mitochondrial
ROS generation. Moreover, NO can facilitate superoxide
scavenging indirectly by stabilizing cytochrome C and
preventing its leakage from mitochondria [24].
Asymmetrical dimethyl L-arginine (ADMA), an endog-
enous NO synthase inhibitor [62], may lead to increased
mitochondrial ROS levels [63]. Mitochondrial ROS pro-
duction can also be increased by the mitochondrial
p66Shc protein, which also favors cytochrome C release,
the dissipation of mitochondrial transmembrane poten-
tial and apoptosis [64-67].
Mitochondrial DNA oxidative damage
Mitochondrial DNA (mtDNA) is probably the most sensi-
tive cellular target of ROS since it is located close to the
inner mitochondrial membrane, where ROS are pro-
duced. Moreover, mtDNA is small in size and is not pro-
tected by histone proteins as is the case for nuclear DNA
[68,69]. Many different types of oxidative DNA lesions
have been described, ranging from base or sugar adduct
modifications to single and double-strand breaks [70].
The hydroxyl radical can remove protons from deoxyri-
bose, thus producing a sugar radical and inducing strand
breaks and release of the affected DNA base [71]. Moreo-
ver, the hydroxyl radical can also abstract a proton from
the methyl group of thymine and add it to the C4, C5 and
C8 position of purines, thereby generating hydroxy
adduct radicals [72].
mtDNA damage correlates with the extent of ATS [16],
suggesting that mitochondrial dysfunction may promote
atherogenesis [1,18,19]. Many of the DNA modifications
can contribute to aging, cancer and neurodegenerative
diseases [73], as well as to several other pathophysiologi-
cal conditions [74]. Damage to mtDNA can have a greater
impact on cellular function than damage to nuclear DNA
[75].
The accumulation of mtDNA mutations can cause cell
dysfunction by altering oxidative phosphorylation and
Ca2+ homeostasis, inducing further oxidative stress and a
defective turnover of mitochondrial proteins, and affect-
ing the susceptibility to apoptosis [49]. In particular, the
mtDNA encoded respiratory enzymes increase electron
leak and ROS production, with subsequent enhanced oxi-
dative stress and further damage to mitochondria [76]. A
vicious cycle may therefore be generated, leading to pro-
gressive accumulation of ROS and oxidative damage to
mtDNA [19].
Dyslipidemia
Both cholesterol and oxidized low density lipoprotein
(oxLDL) can cause mitochondrial damage [17]. Choles-
terol feeding in rabbits is associated with impaired mito-Journal of Biomedical Science 2009, 16:112 http://www.jbiomedsci.com/content/16/1/112
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chondrial function [77]. Similarly, hypercholesterolemia
induced mtDNA damage in heart homogenates [78]. Free
cholesterol (FC) loading of macrophages [79] is associ-
ated with mitochondrial dysfunction, as suggested by
decrease in mitochondrial transmembrane potential and
activation of the mitochondrial apoptosis pathway, a
process playing a key role in atherogenesis. In addition to
the involvement of the classic apoptotic Fas pathway, in
FC-loaded macrophages there is evidence of mitochon-
drial cytocrome C release, caspase 9 activation and
increased levels of the proapoptotic protein Bax [80].
The role of redox regulation and lipid rafts in macro-
phages during ox-LDL-mediated foam cell formation has
recently been reviewed [81]. Circulating ox-LDL repre-
sents an independent risk factor for ATS and acute cardio-
vascular diseases. Ox-LDL causes the mitochondrial
production of ROS in endothelial cells, a process associ-
ated with apoptosis [82,83], through the activation of
mitochondrial complex II [84], uncoupled eNOS, and the
NADPH oxidases [85]. The exposure of endothelial pro-
genitor or mature cells to ox-LDL results in an increased
production of mitochondria-derived superoxide, with
associated increase in p53 expression and subsequent acti-
vation of Bax. The activated Bax translocates into the mito-
chondria to release cytochrome C, which elicits the
apoptotic reaction. Bax is a member of multidomain Bcl-
2 proapoptotic proteins, and its activation and transloca-
tion into the mitochondria has been shown to cause mito-
chondrial dysfunction and cell apoptosis [86]. Cheng et al
[84] have demonstrated that superoxide anion, but not
hydrogen peroxide, can activate p53 and Bax. The super-
oxide regulation of Bax does not consist in an increase in
Bax expression, but rather in an activation through a con-
formational change.
Vindis et al. [87] have recently shown the involvement of
two distinct calcium-dependent mechanisms in ox-LDL-
induced apoptosis: the first is mediated by calpain/mito-
chondrial permeability transitionpore/cytochrome C/cas-
pase, while the second is mediated by a mitochondrial
apoptosis inducing factor, which is cyclosporin-insensi-
tive and caspase-independent. Ox-LDL induces apoptosis
in all cells involved in ATS: endothelial cells, VSMCs, mac-
rophages, and T lymphocytes [88,89].
Diabetes
Type 2 diabetes mellitus (T2DM) is a multifactorial, het-
erogeneous, polygenic disease that accounts for > = 90%
of all types of diabetes. In T2DM insulin resistance is the
major pathologic feature, which often causes a compensa-
tory increase of insulin secretion [90]. ROS are now con-
sidered a major factor in the onset and development of
T2DM. ROS can induce inactivation of the signaling path-
way between the insulin receptor and the glucose trans-
porter system, leading to insulin resistance [91]. On the
other hand, in addition to being a possible effect of ROS
production, T2DM is also a cause of oxidative stress, with
ensuing atherogenic effect [92]. Hyperglycemia induces
superoxide generation in endothelial cells, and most of
this superoxide may be produced by mitochondria [93].
In diabetes, electron transfer and oxidative phosphoryla-
tion are uncoupled, resulting in superoxide formation and
inefficient ATP synthesis [23]. Prevention of oxidative
damage represents a therapeutic strategy in diabetes [23].
In T2DM the elevation of free fatty acid (FFA) concentra-
tions, with subsequent intramyocellular lipid accumula-
tion, has been proposed as a cause of further insulin
resistance and also pancreatic beta-cell death [94,95]. It
has been reported [96,97] that both glucose and FFAs may
initiate the formation of ROS via mitochondrial and
NADPH oxidase mechanisms in muscles, adipocytes, beta
cells and other cells. FFAs penetrate cellular organelles
including mitochondria, where high ROS levels will result
in lipid peroxidation and mitochondrial injury [98].
Interestingly, recent studies revealed that T2DM and insu-
lin resistance are associated with a decreased mitochon-
drial oxidation function in skeletal muscle [99].
Moreover, in T2DM mitochondria are smaller, round and
prone to produce superoxide [100]. Disorders of the mito-
chondrial transport chain, overgeneration of ROS and
lipoperoxides or impairments in antioxidant defenses
have been reported in T2DM, as well as in obesity.
Hypertension
Like other risk factor for ATS, human hypertension is a
condition associated with endothelial dysfunction and
oxidative stress [101-107]. Mitochondrial dysfunction has
been potentially implicated in both human and experi-
mental hypertension [108,109]. Deterioration of mito-
chondrial energy production plays a role in the
pathogenesis of hypertension in both spontaneously
hypertensive rats (SHRs) [110,111] and mice [112]. Mito-
chondrial energy deficiency [113] and a decreased activity
of complex IV have been observed in the hypertrophied
myocardium from SHRs [114]. In these animals there is
also an abnormal transport of inorganic phosphate in left
ventricular mitochondria [115]. Overall, these data indi-
cate that some defect in the regulation of mitochondrial
ATP synthase activity occurs in the cardiomyocites of
SHRs. In addition, mitochondrial calcium overload could
significantly contribute to the development of hyperten-
sive states [113].
An association of hypertension with mitochondrial
uncoupling proteins (UCPs) has been reported both in
experimental and human hypertension. In particular,
mice with doxycycline-inducible expression of UCP 1 inJournal of Biomedical Science 2009, 16:112 http://www.jbiomedsci.com/content/16/1/112
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arterial walls develop hypertension and dietary ATS [112].
A common polymorphism of the UCP2 gene was associ-
ated with hypertension in a Japanese population, and
with hypertension and obesity in Caucasians [116].
ROS and RNS can damage mtDNA [117], with decreased
energy production, additional generation of ROS, and
enhancement of the cellular signals capable of initiating
hypertension, as well as ATS [117]. mtDNA mutations
have been demonstrated in black Americans with hyper-
tension-associated end-stage renal disease [118]. Moreo-
ver, it has been shown that a mutation in mitochondrial
tRNA is associated with hypertension, hypercholestero-
lemia and hypomagnesemia [119]. The putative role of
mitochondrial dysfunction in hypertension has been
recently reviewed [120].
Aging, hyperhomocysteinemia, cigarette smoking and HIV 
as risk factors
Aging significantly increases the risk of coronary heart dis-
ease and other vascular diseases. Several human and ani-
mal studies have shown an age-related impairment of
mitochondrial respiratory chain function and ATP synthe-
sis, together with an accumulation of oxidative mtDNA
mutations [18]. It has been suggested that mitochondrial
dysfunction is a major contributor to aging and aging-
associated ATS [18].
Elevated plasma homocysteine is an independent risk fac-
tor for ATS. It has been proposed that endothelial dysfunc-
tion and ATS can be induced by homocysteine through
increased generation of ROS and reduced NO availability
[121-124]. Austin e al. [125] have shown that homo-
cysteine promotes mitochondrial damage and alters mito-
chondrial gene expression and function. Further,
homocysteine stimulates the expression of NRF1 and T-
fam, two nuclear transcription factors involved in the
modulation of mitochondrial biogenesis. This effect was
prevented by pre-treatment with antioxidants, suggesting
that ROS are important mediators of the effects of homo-
cysteine. In addition, homocysteine induces endothelial
cell apoptosis through mitochondrial mechanisms
[126,127].
Cigarette smoking may significantly increase the risk of
early ATS by affecting mitochondrial function. In fact, in
addition to endothelial injury, platelet activation and LDL
oxidation, the atherogenic effects of cigarette smoking
include oxidative mtDNA damage with mtDNA deletions
and loss of mitochondrial membrane potential [13,128-
131].
Finally, mitochondrial dysfunction can also be considered
a contributing factor for HIV-associated ATS [132-134].
Thus, a range of seemingly unrelated conditions has
underlying pathophysiological mechanisms in common,
namely ROS production and accumulation of mtDNA
damage, resulting in mitochondrial dysfunction and ATS.
Conclusion
Based on experimental evidence and clinical studies, oxi-
dative and nitrosative stress have been shown to be
induced by ATS risk factors and to contribute to the onset
and development of atherosclerotic vascular damage.
Moreover, endogenous risk factors, such as hypertension
and diabetes, may be both the cause of vascular ROS gen-
eration and a consequence of ROS induced endothelial
dysfunction.
Under physiological conditions, the mitochondrial respi-
ratory chain is a major source of superoxide and other
ROS [135-139]. This mechanism may be triggered by risk
factors, with subsequent endothelial dysfunction and
atherogenesis. On the other hand, mitochondria may be
not only a relevant source, but also a target of ROS
[14,15]. In fact, an excessive production of ROS in mito-
chondria will damage lipids, carbohydrates, and proteins,
as well as mtDNA. Indeed, oxidative mtDNA mutations
could represent an important step in the chain of events
connecting risk factors to atherogenesis, acting as further
causes of ROS generation [78,140]. Ballinger et al. [16]
suggested that mitochondrial damage in an early stage can
predict ROS and RNS-mediated atherosclerotic lesions.
Overall, the pathogenetic role of mitochondrial dysfunc-
tion in atherogenesis may now be considered more than a
plausible hypothesis [19].
Despite the experimental evidence of the importance of
oxidative stress in inducing ATS, clinical studies have been
unable to demonstrate that antioxidants have any effect
on human atherogenesis [141-143]. Some studies have
shown that antioxidants such as alpha tocopherol, ubiq-
uinone and N-acetylcysteine could decrease mitochon-
drial oxidative damage in different experimental models
[144-148]. However, the effectiveness of these com-
pounds is limited, since they do not significantly accumu-
late within mitochondria [149], and strategies for the
targeted delivery of antioxidants to mitochondria are now
in the developmental stages [150]. In fact the antioxidant
moieties can be bound by covalent attachment to
lipophilic triphenylphosphonium cations, which, due to
the large mitochondrial membrane potential, do accumu-
late within the mitochondria [151]. The targeted version
of ubiquinol (MitoQ) has been used most extensively
[151,152], and is now being tested in man as an oral drug
for the treatment of hepatitis C [153] and Parkinson's dis-
ease [154]. However, despite these promising data, more
pre-clinical and clinical studies are needed in order toJournal of Biomedical Science 2009, 16:112 http://www.jbiomedsci.com/content/16/1/112
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evaluate both the effectiveness and the safety of mito-
chondria targeted antioxidants.
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